Figure 4.

Members of the mTOR pathway and their inhibitors. Several inhibitors of the mTOR pathway have been developed in recent years, and most of them are currently studied in clinical trials. Red color indicates inhibitors, which are currently studied in clinical trials, while blue color indicates inhibitors in the preclinical phase. List of abbreviations: Akt, protein kinase B; ILK, integrin-linked kinase; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; PI3K, phosphatidylinositol 3-kinase; Rictor, rapamycin-insensitive companion of mTOR.